|Bid||61.03 x 1300|
|Ask||64.78 x 800|
|Day's Range||61.03 - 62.63|
|52 Week Range||30.90 - 82.49|
|Beta (5Y Monthly)||0.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
One of Cambridge’s emerging gene therapy startups has raised $110 million to support the company as it heads toward in-human trials. Generation Bio closed the Series C round this week, bringing in new investors T. Rowe Price, Farallon and Wellington Management, as well as previous backers Atlas Venture, Fidelity and others. The Series C round brings the total money raised by Generation Bio to more than $235 million.
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Massachusetts life science companies were involved in $34 billion worth of mergers and acquisitions this year. Experts say next year will be even busier.
Two of the industry’s leading gene-editing experts have unveiled their next venture: a gene-silencing startup called Triplet Therapeutics.
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
Companies with gene therapy capabilities are becoming more attractive to members of Big Pharma, who are eager to add the technology to their portfolios Continue reading...
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Gene therapy company Audentes Therapeutics Inc (NASDAQ: BOLD ) announced a deal late Monday to be acquired by Japanese pharma company ASTELLAS PHARMA/ADR (OTC: ALPMY ) for $60 per share, representing a ...
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]
The company is in early stages of testing gene and cell therapies they hope will deliver 'transformative and curative' treatments Continue reading...
uniQure (QURE) delivered earnings and revenue surprises of 30.12% and -53.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The Emeryville company says it has improved on the traditional way of delivering corrected copies of genes.
Peter A. Wright launched P.A.W. Capital Partners back in 1990. He is the fund’s Chief Investment Officer, General Partner and Senior Portfolio Manager ever since. He holds a BS in Chemical Engineering and an MBA from Cornell University. Mr. Wright started off his career at I.B.M, later moving to Gartner Group where he worked as an […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 4) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Bioanalytical ...